


MAR 28 2005



2 FW

**Certificate of Mailing 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to **MAIL STOP AMENDMENT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Signing Certificate: \_\_\_\_\_

Helene Gabel

March 25, 2005  
Date

Helene Gabel  
Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Named Inventor: Ruey J. Yu, et al

§  
§  
§  
§  
§  
§  
§

Conf. No.: 2318

§ Group Art Unit: 1614

Appln. No.: 10/817,479

§ Examiner: Not Yet Assigned

Filing Date: April 2, 2004

§ Attorney Docket No.: 8976-227U1

Title: TOPICAL TREATMENT OF DERMATOLOGICAL DISORDERS ASSOCIATED  
WITH REACTIVE OR DILATED BLOOD VESSELS

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.97(b)**

Enclosed is an Information Disclosure Citation Form PTO/SB/08A, in accordance with 37 C.F.R. § 1.98(a)(1) and (a)(2), listing all patents, publications, applications and/or other information being submitted for consideration which may be material to the patentability of this application and/or for which there may be a duty to disclose in accordance with 37 C.F.R. §1.56. Copies of the listed U.S. patents are not enclosed. However, we will provide copies upon request.

The references were cited in a communication mailed 24 January 2005 (copy enclosed) from the International Searching Authority of the U.S. Patent and Trademark Office concerning counterpart International Application No. PCT/US04/10454, filed 5 April 2004.

The filing of this Information Disclosure Statement shall not be construed as an admission that any of the listed documents constitutes prior art, nor as an admission against interest in any manner.

No fee is believed to be due in connection with the filing of this Information Disclosure Statement since it is being filed before the mailing date of the first Office Action on the merits. However, the Commissioner is hereby authorized to charge any deficiencies or credit any overpayments to Deposit Account No. 50-1017.

It is respectfully requested that this Information Disclosure Statement and the documents listed on the attached Form PTO/SB/08A and/or B be considered and acknowledged by the Examiner in connection with the above-identified patent application, be made of record therein, and that the listed document(s) be cited in the issued patent.

Respectfully submitted,

**RUEY J. YU *et al.***



**ALAN S. NADEL**

Attorney/Agent for Applicant(s)

Registration No. 27,363

Direct Dial: 215-965-1280

E-Mail: [anadel@akingump.com](mailto:anadel@akingump.com)

March 25, 2005  
(Date)

Akin Gump Strauss Hauer & Feld LLP  
One Commerce Square  
2005 Market Street, Suite 2200  
Philadelphia, PA 19103  
Telephone No.: 215-965-1200  
Fax No.: 215-965-1210

ASN:hg  
Enclosures

Form PTO/SB/08A

**SUPPLEMENTAL  
INFORMATION  
DISCLOSURE STATEMENT  
BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	10/817,479
<b>Filing Date</b>	April 2, 2004
<b>First Named Inventor</b>	Ruey J. Yu, et al
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	Not Yet Assigned
<b>Attorney Docket Number</b>	8976-227U1

## U.S. PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Date Considered	
-----------------	--